{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343421","form_type":"8-K","ticker":"COAG","cik":"0002114044","company_name":"Hemab Therapeutics Holdings, Inc.","filed_at":"2026-08-11T11:11:07+00:00","discovered_at":"2026-08-11T11:15:00.441918+00:00","generated_at":"2026-08-11T11:15:21.266669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hemab Q2 net loss $24.2M; FDA clears sutacimig Phase 3 in Glanzmann thrombasthenia","bullets":["Net loss $24.2M ($0.80/share) vs $12.2M ($12.91/share) YoY; cash $457.5M, runway into 2029.","FDA endorsed sutacimig data package for Phase 3 pivotal trial in GT; initiation planned 2H 2026.","HMB-002 proof-of-mechanism: ≥2.4-fold VWF/FVIII increase; 8/9 patients zero treated bleeds post-dose.","Unveiled HMB-003, novel peptide plasmin inhibitor for heavy menstrual bleeding; FIH trials 2H 2026.","R&D expense $20.3M vs $12.9M; G&A $5.7M vs $3.2M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343421","json":"https://secwatch.observer/filing/0001193125-26-343421.json","markdown":"https://secwatch.observer/filing/0001193125-26-343421.md","text":"https://secwatch.observer/filing/0001193125-26-343421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/0001193125-26-343421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/d180684d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:15:21.266669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}